INVA
NASD Innoviva, Inc.$21.21 ↑ +0.00 (+0.00%) Trading Up from the previous close of $21.21, $0.07 below the day’s high of $21.28
- YTD change
- +6.10%
- vs 20-day SMA
- +1.62%
- vs 200-day SMA
- -2.62%
Price ranges
Price & Performance
-2.99 (-12.36%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 15.6% away from all-time highs of $25.15
- INVA is up 6% since the beginning of the year
- INVA is up 22% over the past 12 months
- INVA is up 3% over the past 1 month
- 10% of all INVA investors are betting against INVA
INVA reads very good: price sits above one of the two key moving averages, the 12-month move is +21.5%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- +3.21%
- vs 8-day SMA
- +1.74%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.